Background -Patients with non-tuberculous mycobacteria are usually started on conventional antituberculous triple therapy once acid fast bacilli are detected, before the exact type of mycobacteria has been identified. The ability to identify the characteristics of patients with tuberculous and non-tuberculous mycobacteria may be helpful in identifying before treatment those patients more likely to have non-tuberculous infection. Methods -A retrospective study was conducted of all patients in one unit in whom non-tuberculous mycobacteria were identified in sputum or bronchoalveolar washings in the period 1987-93. 
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CAL= chronic airflow limitation. * Although AIDS was included as a pre-existing lung disease, infection with non-tuberculous mycobacteria was the only respiratory manifestation of AIDS in all five patients. infection were included in the study if at least three colonies were isolated from two samples. The case notes and chest radiographs of all patients with non-tuberculous mycobacteria were reviewed. Data regarding age, sex, ethnic origin, underlying lung disease or AIDS, pattern of resistance to first line drugs, and outcome oftreatment were collected. Patients were considered to have chronic airflow limitation when there was a clear history, radiographic evidence, and respiratory function data to suggest chronic asthma or chronic obstructive pulmonary disease. Patients were considered to have been treated if they received at least six months of therapy. Relapse was considered to have occurred when the same type of mycobacterium was isolated from sputum after cessation of treatment, with or without radiographic changes. Data on relapse were collected for all patients diagnosed between January 1987 and December 1991.
Patients with culture positive M tuberculosis diagnosed within the same period were used as a control group.
DATA ANALYSIS
Frequency of factors seen in tuberculosis and non-tuberculous mycobacteria were compared using the X2 test. Age was compared using the two tailed t test.
Results
Over the seven year study period non-tuberculous mycobacteria and M tuberculosis were cultured from sputum or bronchoalveolar lavage fluid in 70 and 221 patients, respectively. Non-tuberculous mycobacteria were typed as follows: M xenopi 23 cases (33%), M kansasii 19 (27%), Mfortuitum 14 (20%), M chelonae 5 (7%), M malmoense 3 (4%), M gordonae 2 (3%), M avium intracellulare 2 (3%), M scrufulacium 1 (15%), and M bovis 1 (1-5%) (figure).
Patients with non-tuberculous mycobacteria were older than those with tuberculosis, and most were white subjects ( Comparison of non-tuberculous mycobacterial infection and pulmonary tuberculosis All isolates of M kansasii and all but one of M xenopi were susceptible to rifampicin and ethambutol.
Sensitivity to streptomycin was seen in all but one isolate of M xenopi (95%) and in 13 cases (68%) of M kansasii. M fortuitum was highly resistant to most first line drugs. In seven cases of tuberculosis the organism was resistant to one (four patients) or more than one (three patients) first line drugs.
All patients with tuberculosis were treated. Treatment was felt to be appropriate in most of the patients with M xenopi and M kansasii (71% and 64%, respectively). The duration of treatment ranged from six to 28 months (median 15 months), and the outcome is shown in table 3. The major reasons for non-treatment were lack of symptoms and/or radiographic signs, or the presence of advanced underlying lung disease. Spontaneous sputum clearance was seen in one case of M xenopi and in seven cases of M fortuitum, but in no cases of M kansasii.
For patients diagnosed before January 1991 and in whom reliable data were available, relapse occurred in six of 10 patients with M xenopi, one of five with M kansasii, and in 11 of 157 with tuberculosis.
Discussion
In this study non-tuberculous mycobacteria were isolated mainly from older white patients, whereas culture positive tuberculosis affected a younger population of both white patients and those from the ethnic minorities. M xenopi and M kansasii were most frequently detected, reflecting the distribution of mycobacteria found in south east England. 4 As in previous studies,5 7 the types of lung disease most frequently associated with nontuberculous mycobacterial infection were chronic obstructive airway disease, lung cancer, and previous tuberculosis.
All isolates of M kansasii were sensitive to rifampicin and ethambutol. This is consistent with previous studies.8'-0 For M xenopi more than 25% of isolates were fully sensitive and all but one were susceptible to rifampicin and ethambutol. These findings are in contrast with a previous study by Banks et The relapse rate was high in patients with M xenopi, reaching 60%. In a previous study Banks reported relapse in 26% of patients with M xenopi after sufficient treatment with a combination containing isoniazid, rifampicin, ethambutol, and streptomycin. As M xenopi is widespread in the environment, reinfection is also possible no matter what treatment regimen has been used. For M kansasii relapse occurred in one of the five patients (20%) who had a sufficiently long follow up period. In previous retrospective studies569 relapse rates of 0-34% have been described. In the prospective study conducted by the British Thoracic Society the relapse rate for M kansasii was 9 7%.10
Treatment was started on clinical grounds in two cases of M fortuitum; however, both patients subsequently died of their underlying disease (lung cancer and AIDS).
Establishing the relationship between nontuberculous mycobacteria and the lungs is often difficult, but three types of relationship have been proposed.8 The first is colonisation, defined as isolation of mycobacteria without conversion of the skin test and with no clinical or radiographic signs of infection; the second is subclinical infection where the skin test becomes positive without any clinical or radiographic signs; and the third is clinical disease with symptoms and signs of infection. Skin tests were not performed in any of the patients in our study. The spontaneous clearance of M fortuitum in over half of the cases, however, suggests colonisation or subclinical infection rather than clinical disease.
Our retrospective study suggests that, when mycobacteria are isolated from an older white population with pre-existing lung disease, consideration should be given as to whether this is a non-tuberculous infection. A combination containing rifampicin and ethambutol is suggested when infection with non-tuberculous mycobacteria is suspected. The relapse rate for M xenopi is high, and a prospective study of the effect of the above combination of treatment is needed.
